🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in France / NCT07361575
Starting soon Not applicable

Study Comparing the Quality of Colon Cleanliness With Prepackaged LRD (Low-residue Diet) vs. Guided (POG).

NCT07361575 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-01-30
Last updated
2026-02-17

Condition(s) studied

Colorectal Cancer PreventionColorectal Cancer (Diagnosis)Colorectal Adenocarcinoma

Investigational drug(s) / intervention(s)

ColonoscopyQuestionnairesPre-colonoscopy diet according to the investigator's oral instructionsPre-colonoscopy diet by following a special preparation, Colobox.

Colonoscopy: Colonoscopy performed and Boston score evaluated

Questionnaires: LRD satisfaction questionnaire LRD compliance questionnaire

Pre-colonoscopy diet according to the investigator's oral instructions: 24 hours before the colonoscopy, The patients follow a special diet, either by themselves according to the investigator's oral instructions

Pre-colonoscopy diet by following a special preparation, Colobox.: 24 hours before the colonoscopy, The patients follow a special diet, by following a special preparation, Colobox.

Study summary

Low-residue diet (LRD) in patient improves the quality of the colon cleanliness and thus the adenoma detection rate (ADR). This is a key criterion in colonoscopy screening for colorectal cancer (CRC). The benefit of an LRD lasting more than 24 hours before colonoscopy has not been demonstrated compared to a 24-hour LRD.

Few studies have evaluated the benefit of a prepackaged 24-hour LRD compared to simply receiving oral and written LRD instructions during a consultation.

The aim of the study is to evaluate the usefulness of a prepackaged LRD (Colobox®) compared to simple LRD instructions on colon cleanliness (Boston score) in patients examined by endoscopy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient of one of the investigators for total colonoscopy (no prior colonic surgery); * Patient aged 18 years or older; * Patient classified as ASA 1, ASA 2, or ASA 3; * Not participating in any other current clinical trial; * Free, informed, and signed consent; * Patient affiliated with or a beneficiary of a social security scheme, according to Article L.1124-1 of the French Public Health Code; Exclusion Criteria: * Patient taking major psychotropic medications; * Patient with uncontrolled diabetes; * Patient with coagulation abnormalities preventing polypectomy: PT \<50%, Platelets \<50,000/mm³, current effective anticoagulation therapy (clopidogrel, prasugrel, or ticagrelor); * Patient referred for removal of a known polyp; * Chronic inflammatory bowel disease; * Known colonic stenosis; * Diverticulitis of less than 6 weeks duration; * Pregnant, parturient, or breastfeeding woman; * Patient deprived of liberty by administrative or judicial order, or under guardianship or limited legal protection; * Patient unable to understand the objectives and constraints of the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Clinique Paris Bercy Charenton-le-Pont France

More Clinique Paris-Bercy trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07361575 on ClinicalTrials.gov ↗ ← All trials in France